Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Carboplatin and Pembrolizumab Chemoimmunotherapy Achieves Remission in Recurrent, Metastatic Sebaceous Carcinoma

Kodali, Saranya, M.D.*; Tipirneni, Eswar, M.D.*; Gibson, Pamela C., M.D.; Cook, Deborah, M.D.; Verschraegen, Claire, M.D.; Lane, Katherine A., M.D.§

Ophthalmic Plastic & Reconstructive Surgery: September/October 2018 - Volume 34 - Issue 5 - p e149–e151
doi: 10.1097/IOP.0000000000001164
Case Reports

A 72-year-old Caucasian woman who had recurrent sebaceous carcinoma of the right orbit with bilateral cervical lymph node involvement 24 months after orbital exenteration was treated with carboplatin (area under the curve of 5) and pembrolizumab (2 mg/kg) for 6 cycles, followed by maintenance pembrolizumab. She obtained a complete pathological remission and remains free of local, regional, and systemic disease at 15 months.

The authors discuss an aggressive recurrence and metastasis of orbital sebaceous carcinoma treated with the chemoimmunotherapy combination carboplatin and pembrolizumab, an antiprogrammed death-1 immunotherapeutic.

*Division of Hematology Oncology, University of Vermont Cancer Center, Burlington, Vermont

Division of Anatomic Pathology, University of Vermont Medical Center

Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

§Ophthalmic Consultants of Vermont, South Burlington, Vermont, U.S.A.

Accepted for publication May 1, 2018.

The authors have no financial or conflicts of interest to disclose.

Address correspondence and reprint requests to Katherine A. Lane, M.D., Ophthalmic Consultants of Vermont, South Burlington, VT.

© 2018 by The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc., All rights reserved.